Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Alder BioPharma Files for $115M IPO

By Drug Discovery Trends Editor | March 19, 2014

Drug developer Alder BioPharmaceuticals on Wednesday filed for an initial public offering worth as much as $115 million.
 
The company is studying an experimental migraine prevention drug designated ALD403 and is working with Bristol-Myers Squibb Co. on a rheumatoid arthritis and psoriatic arthritis treatment called clazakizumab. Both products are in mid-stage clinical testing. Alder said it is working to develop antibody drugs that are more effective, work faster, and produce longer-lasting biologic responses.
 
Alder BioPharmaceuticals Inc. said it could get a total of $1.35 billion in payments if clazakizumab advances through the clinical testing and regulatory process, gets approved, and reaches sales targets. The company will also receive royalty payments on any sales. So far it has received $103.5 million from Bristol-Myers under a deal the companies signed in 2009.
 
In 2013, Alder posted a loss of $20.6 million, or $3.84 per share, on collaboration and license revenue of $18.8 million.
 
It plans to use proceeds from the IPO to fund its clinical programs and for general corporate purposes.
 
The Bothell, Wash., company plans to list its shares on the Nasdaq Global Market under the symbol “ALDR.”
 
Date: March 20, 2014
Source: Associated Press
 

Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE